advertisement
Abstract #25960 Published in IGR 12-2
The efficacy and safety of two fixed combinations: timolol-dorzolamide-brimonidine versus timolol-dorzolamide. A prospective, randomized, double-masked, multi-center, 6-month clinical trial
Baiza-Duran LM; Alvarez-Delgado J; Contreras-Rubio AY; Medrano-Palafox J; De Luca-Brown A; Casab-Rueda H; Cortes-Gastelum MA; Garciduenas-Mejia MJ; Gomez-Bastar P; Gil-Carrasco FAnnals of ophthalmology (Skokie, Ill.) 2009; 41: 174-178
We compared the efficacy and safety of a new fixed combination of timolol 0.5%/odorzolamide 20%/brimonidine 0.2% in ophthalmic solution versus a fixed combination of timolol 0.5%/dorzolamide 2% in patients with open-angle glaucoma or ocular hypertension. The fixed triple combination was significantly more efficient in mean intraocular pressure reduction from baseline throughout the six-month follow-up.
L.M. Baiza-Duran. Clinical Research Department, Laboratorios Sophia, S.A. de C.V. Guadalajara, Jalisco, Mexico. drbvista@sophia.com.mx
Classification:
11.13.2 Betablocker and carbon anhydrase inhibitor (Part of: 11 Medical treatment > 11.13 Combination therapy)
11.13.3 Betablocker and brimonidine (Part of: 11 Medical treatment > 11.13 Combination therapy)
